R2med

History

2021: Exit of Rusatom Healthcare from P2med

At the end of November 2021, it became known about the withdrawal of the company Rusatom Healthcare"" ("daughter" ") Rosatom from a joint venture with" R-farm"- LLC" R2med. " This company produces radiopharmaceuticals used to treat severe diseases.

Rosatom left a multibillion-dollar joint venture with R-Farm for the production of radiopharmaceuticals

According to Sheets"" with reference to these systems, SPARK-Interfax"" since October 2021, the only owner of R2med LLC is R-Farm.

The representative of Rusatom Healthcare confirmed to the publication the fact that the company left the joint venture. According to him, 50% of the shares in R2med were sold to R-Farm. He did not disclose the amount of the transaction. He explained his decision by "updating the development strategy" by Rusatom Healthcare.

The representative of R-Farm added that the company will continue to implement the project independently, the first production cycle is planned to be launched in 2022.

2019: Company Approval

In 2019, R-Pharm JSC and Rusatom Healthcare JSC established R2Med LLC on a parity basis. A joint venture has been created to execute an offset contract (i.e. implying a long-term supply agreement with counter investment obligations) for 18.4 billion rubles, which R-Farm concluded with the Moscow City Hall.

The agreement suggested that R-Farm would invest at least 3 billion rubles in organizing the production of 31 names of drugs for the treatment of oncological, cardiovascular and other diseases, and the mayor's office, in turn, should purchase them until 2028. The contract did not prohibit the involvement of partners, and the company attracted to the Rusatom Healthcare project.

Rusatom Healthcare explained its interest in cooperation with R-Pharm by the prospect of producing radiopharmaceuticals, pharmaceutical stations and generators.

The creation of a ready-made innovative radiopharmaceutical product - a radiopharmaceutical product - is impossible without the production of a wide range of carrier molecules, the so-called "cold" sets, "said Denis Cherednichenko, CEO of Rusatom Halskea.[1]

Notes